249 related articles for article (PubMed ID: 25489844)
1. Valganciclovir administration to kidney donors to reduce the burden of cytomegalovirus and Epstein-Barr virus transmission during transplantation.
Verghese PS; Schmeling DO; Knight JA; Matas AJ; Balfour HH
Transplantation; 2015 Jun; 99(6):1186-91. PubMed ID: 25489844
[TBL] [Abstract][Full Text] [Related]
2. Valacyclovir or valganciclovir for cytomegalovirus prophylaxis: A randomized controlled trial in adult and pediatric kidney transplant recipients.
Verghese PS; Evans MD; Hanson A; Hathi J; Chinnakotla S; Matas A; Balfour HH
J Clin Virol; 2024 Jun; 172():105678. PubMed ID: 38688164
[TBL] [Abstract][Full Text] [Related]
3. The impact of donor viral replication at transplant on recipient infections posttransplant: a prospective study.
Verghese PS; Schmeling DO; Knight JA; Matas AJ; Balfour HH
Transplantation; 2015 Mar; 99(3):602-8. PubMed ID: 25148381
[TBL] [Abstract][Full Text] [Related]
4. The efficacy of valganciclovir for prevention of infections with cytomegalovirus and Epstein-Barr virus after kidney transplant in children.
Cameron BM; Kennedy SE; Rawlinson WD; Mackie FE
Pediatr Transplant; 2017 Feb; 21(1):. PubMed ID: 27704725
[TBL] [Abstract][Full Text] [Related]
5. A randomized trial of ganciclovir versus ganciclovir plus immune globulin for prophylaxis against Epstein-Barr virus related posttransplant lymphoproliferative disorder.
Humar A; Hébert D; Davies HD; Humar A; Stephens D; O'Doherty B; Allen U
Transplantation; 2006 Mar; 81(6):856-61. PubMed ID: 16570008
[TBL] [Abstract][Full Text] [Related]
6. Impact of a preemptive strategy after 3 months of valganciclovir cytomegalovirus prophylaxis in kidney transplant recipients.
Boillat Blanco N; Pascual M; Venetz JP; Nseir G; Meylan PR; Manuel O
Transplantation; 2011 Jan; 91(2):251-5. PubMed ID: 21099744
[TBL] [Abstract][Full Text] [Related]
7. Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-year results of a randomized clinical trial.
Witzke O; Hauser IA; Bartels M; Wolf G; Wolters H; Nitschke M;
Transplantation; 2012 Jan; 93(1):61-8. PubMed ID: 22094954
[TBL] [Abstract][Full Text] [Related]
8. Does valganciclovir hydrochloride (valcyte) provide effective prophylaxis against cytomegalovirus infection in liver transplant recipients?
Jain A; Orloff M; Kashyap R; Lansing K; Betts R; Mohanka R; Menegus M; Ryan C; Bozorgzadeh A
Transplant Proc; 2005 Sep; 37(7):3182-6. PubMed ID: 16213344
[TBL] [Abstract][Full Text] [Related]
9. Extended valganciclovir prophylaxis to prevent cytomegalovirus after lung transplantation: a randomized, controlled trial.
Palmer SM; Limaye AP; Banks M; Gallup D; Chapman J; Lawrence EC; Dunitz J; Milstone A; Reynolds J; Yung GL; Chan KM; Aris R; Garrity E; Valentine V; McCall J; Chow SC; Davis RD; Avery R
Ann Intern Med; 2010 Jun; 152(12):761-9. PubMed ID: 20547904
[TBL] [Abstract][Full Text] [Related]
10. Pretransplant prophylactic rituximab to prevent Epstein-Barr virus (EBV) viremia in EBV-seronegative kidney transplant recipients from EBV-seropositive donors: results of a pilot study.
Schachtner T; Reinke P
Transpl Infect Dis; 2016 Dec; 18(6):881-888. PubMed ID: 27632022
[TBL] [Abstract][Full Text] [Related]
11. Subclinical cytomegalovirus and Epstein-Barr virus viremia are associated with adverse outcomes in pediatric renal transplantation.
Li L; Chaudhuri A; Weintraub LA; Hsieh F; Shah S; Alexander S; Salvatierra O; Sarwal MM
Pediatr Transplant; 2007 Mar; 11(2):187-95. PubMed ID: 17300499
[TBL] [Abstract][Full Text] [Related]
12. (Val-)Ganciclovir prophylaxis reduces Epstein-Barr virus primary infection in pediatric renal transplantation.
Höcker B; Böhm S; Fickenscher H; Küsters U; Schnitzler P; Pohl M; John U; Kemper MJ; Fehrenbach H; Wigger M; Holder M; Schröder M; Feneberg R; Köpf-Shakib S; Tönshoff B
Transpl Int; 2012 Jul; 25(7):723-31. PubMed ID: 22533698
[TBL] [Abstract][Full Text] [Related]
13. Cytomegalovirus serostatus pairing and deceased donor kidney transplant outcomes in adult recipients with antiviral prophylaxis.
Kuo HT; Ye X; Sampaio MS; Reddy P; Bunnapradist S
Transplantation; 2010 Nov; 90(10):1091-8. PubMed ID: 20885340
[TBL] [Abstract][Full Text] [Related]
14. Oral ganciclovir versus low-dose valganciclovir for prevention of cytomegalovirus disease in recipients of kidney and pancreas transplants.
Weng FL; Patel AM; Wanchoo R; Brahmbhatt Y; Ribeiro K; Uknis ME; Mulgaonkar S; Mathis AS
Transplantation; 2007 Feb; 83(3):290-6. PubMed ID: 17297403
[TBL] [Abstract][Full Text] [Related]
15. Cytomegalovirus and Epstein-Barr virus infections among pediatric kidney transplant recipients at a center using universal Valganciclovir Prophylaxis.
Paulsen G; Cumagun P; Mixon E; Fowler K; Feig D; Shimamura M
Pediatr Transplant; 2019 May; 23(3):e13382. PubMed ID: 30786115
[TBL] [Abstract][Full Text] [Related]
16. A randomized prospective controlled trial of oral ganciclovir versus oral valacyclovir for prophylaxis of cytomegalovirus disease after renal transplantation.
Reischig T; Opatrny K; Bouda M; Treska V; Jindra P; Svecova M
Transpl Int; 2002 Dec; 15(12):615-22. PubMed ID: 12478408
[TBL] [Abstract][Full Text] [Related]
17. Cytomegalovirus disease among donor-positive/recipient-negative lung transplant recipients in the era of valganciclovir prophylaxis.
Mitsani D; Nguyen MH; Kwak EJ; Silveira FP; Vadnerkar A; Pilewski J; Crespo M; Toyoda Y; Bermudez C; Clancy CJ
J Heart Lung Transplant; 2010 Sep; 29(9):1014-20. PubMed ID: 20598582
[TBL] [Abstract][Full Text] [Related]
18. Increased risk of breakthrough infection among cytomegalovirus donor-positive/recipient-negative kidney transplant recipients receiving lower-dose valganciclovir prophylaxis.
Stevens DR; Sawinski D; Blumberg E; Galanakis N; Bloom RD; Trofe-Clark J
Transpl Infect Dis; 2015 Apr; 17(2):163-73. PubMed ID: 25661673
[TBL] [Abstract][Full Text] [Related]
19. A trial of valganciclovir prophylaxis for cytomegalovirus prevention in lung transplant recipients.
Humar A; Kumar D; Preiksaitis J; Boivin G; Siegal D; Fenton J; Jackson K; Nia S; Lien D
Am J Transplant; 2005 Jun; 5(6):1462-8. PubMed ID: 15888055
[TBL] [Abstract][Full Text] [Related]
20. The efficacy and safety of valganciclovir vs. oral ganciclovir in the prevention of symptomatic CMV infection in children after solid organ transplantation.
Lapidus-Krol E; Shapiro R; Amir J; Davidovits M; Steinberg R; Mor E; Avitzur Y
Pediatr Transplant; 2010 Sep; 14(6):753-60. PubMed ID: 20477976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
